Insiders who bought US$82.3k worth of Regulus Therapeutics Inc.'s (NASDAQ:RGLS) stock at an average buy price of US$1.12 over the last year may be disappointed by the recent 19% decrease in the stock.

Throughout the "Harry Potter" books and movies — the original ones, not the "Fantastic Beasts" franchise — there are plenty of mysteries scattered around for both the audience and Harry ...